Thursday May 25th 2017

Archive for September, 2014

National MS Society Invests Nearly $19 Million in New Research to Stop Multiple Sclerosis, Restore F

National MS Society Invests Nearly $19 Million in New Research to Stop Multiple Sclerosis, Restore F

/About-the-Society/News/National-MS-Society-Invests-Nearly-$19-Million-in [Read More]

Neurodegeneration: Active astrocytes drive inflammation

Neurodegeneration: Active astrocytes drive inflammation

Nature Reviews Neuroscience 15, 698 (2014). doi:10.1038/nrn3844 Author: Katherine Whalley Astrocyte activation has been linked to neurodegeneration in conditions such as multiple sclerosis (MS); however, the molecular mechanisms involved are unclear. The authors found that [Read More]

Relapsing multiple sclerosis patients treated with disease modifying therapy exhibit highly variable disease progression: A predictive model

Relapsing multiple sclerosis patients treated with disease modifying therapy exhibit highly variable disease progression: A predictive model

The definition of secondary progressive multiple sclerosis (SPMS) has always been imprecise and subjective, even using the most accepted recommendations for determining the onset of this critical phase of relapse onset multiple sclerosis (RMS) . A systematic scoring system [Read More]

 Page 1 of 102  1  2  3  4  5 » ...  Last » 

Latest Topics

Study finds variations among hospitals in transitioning stroke patients from treatment to comfort care

Study finds variations among hospitals in transitioning stroke patients from treatment to comfort care

Hospitals vary widely in how often they transition people with strokes from active treatment to comfort or hospice care [Read More]

Roche investigating case of patient illness after taking MS drug

Roche investigating case of patient illness after taking MS drug

ZURICH (Reuters) - A person in Germany treated with Roche ’s new multiple sclerosis drug Ocrevus has been diagnosed [Read More]

MS Study Alert: Share Your Thoughts About MS Research

MS Study Alert: Share Your Thoughts About MS Research

/About-the-Society/News/MS-Study-Alert-Share-Your-Thoughts-About-MS-Resea [Read More]

Mallinckrodt begins enrolment in Phase IV trial of HP Acthar gel for RRMS

Mallinckrodt begins enrolment in Phase IV trial of HP Acthar gel for RRMS

UK-based specialist pharmaceutical firm Mallinckrodt has begun patient enrolment in the Phase IV OPTIONS clinical trial [Read More]

First Results Announced from Second Phase III Trial of Oral Ozanimod in People with Relapsing MS

First Results Announced from Second Phase III Trial of Oral Ozanimod in People with Relapsing MS

/About-the-Society/News/First-Results-Announced-from-Second-Phase-III-Tria [Read More]